VC: Neuromed lands $53.3M in fifth round



Neuromed lands $53.3M in fifth round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Neuromed Pharmaceuticals
Canada

$53.3M
Fifth

MPM Capital, James Richardson & Sons, Neuro Discovery, GrowthWorks Capital, BDC Venture Capital, CMDF, and the Royal Bank of Canada

Much of that money is earmarked for clinical trials, including a late-stage study of a newly licensed pain drug.

Nereus Pharmaceuticals
San Diego, CA

$45M
Fourth

BankInvest Biomedical Venture

The money will be drawn down in two tranches and used to complete Phase I and begin Phase II clinical trials for Nereus' two drug candidates.

NeurAxon
Waltham, MA

$32M
Second

Delphi Ventures and OrbiMed Advisors

The money is earmarked for advancing the developer's pain therapies.

Ophthotech
Princeton, NJ

$36M
First

SV Life Sciences

Ophthotech is off and running with a first round of $36 million

Pevion Biotech
Germany

$30.2M
First

BZ Bank Aktiengesellschaft

The company said it will use the funds to push a hepatitis C and breast cancer vaccines into Phase II. It will also fund preclinical vaccine candidates against RSV and Candida infections into clinical development.

Topigen Pharmaceuticals
Canada

$25M
Third

NovaQuest and MMV Financial

The investment is earmarked for Phase II clinical programs relating to its lead products, TPI 1020, a small-molecule drug in development for Chronic Obstructive Pulmonary Disease and TPI ASM8, its RNA-inhibiting therapeutic for asthma.

FoldRx
Cambridge, Mass.

$22M

Cystic Fibrosis Foundation

FoldRx has snagged $22 million from the Cystic Fibrosis Foundation to develop and commercialize new drugs for the condition.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.